2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5877 Chimeric antigen receptor T-cell manufacturing is associated with DNA methylation-based biological aging in B-cell malignancies

Drew R Nannini, DO, PhD, Haitham Abdelhakim, MD2, David Akhavan, MD, PhD3, Joseph P McGuirk, DO4
1 University of Kansas Medical Center, Kansas City, Kansas, United States
2 University of Kansas Medical Center, Kansas City, Kansas, United States
3 University of Kansas Medical Center, Kansas City, Kansas, United States
4 University of Kansas Medical Center, Kansas City, Kansas, United States

Introduction: Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape for patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL) and Non-Hodgkin lymphoma (NHL), yet the biological effects of CAR T-cell manufacturing remain incompletely understood. DNA methylation regulates T-cell differentiation and function, and epigenetic signatures of CAR T-cells have been associated with clinical outcomes. DNA methylation-based measures of biological aging capture age-related molecular changes and may provide a novel framework for evaluating CAR T-cell manufacturing. We examined changes in epigenetic markers of biological aging following CAR T-cell manufacturing.

Methods: Non-transduced and CAR-transduced T-cell samples from adult patients (age 18-70) with R/R ALL (n=37) and NHL (n=35) underwent DNA methylation profiling using the Infinium MethylationEPIC BeadChip and were publicly available (GSE179414). Non-transduced T-cells were derived from apheresis products prior to CAR T-cell manufacturing and compared with CAR-transduced T-cells prior to infusion. Six principal component-based biological aging measures (i.e., intrinsic epigenetic age acceleration [IEAA], SkinBlood age acceleration [SkinBloodAA], extrinsic epigenetic age acceleration [EEAA], PhenoAge acceleration [PhenoAA], GrimAge acceleration [GrimAA], and telomere length attrition [TLA]) were estimated from DNA methylation levels. Linear mixed models evaluated associations between CAR T-cell manufacturing and each biological aging metric adjusting for age, sex, and B-cell malignancy. Interaction and stratified analyses evaluated effect modification by B-cell malignancy. Secondary analyses evaluated associations between DNA methylation-estimated immune cell type proportions of EEAA and DNA methylation-estimated surrogate plasma proteins of GrimAge with CAR T-cell manufacturing.

Results: SkinBloodAA (P=0.039), EEAA (P=0.005), PhenoAA (P=0.001), GrimAA (P<0.001), and TLA (P=0.002) were significantly associated with CAR T-cell manufacturing. CAR-transduced T-cells exhibited a 9-month decrease in SkinBloodAA, a 12-month decrease in EEAA, an 18-month decrease in PhenoAA, a 9-month decrease in GrimAA, and a 0.07-unit increase in TLA compared to non-transduced T-cells. Among the estimated immune cell type proportions of EEAA, CAR-transduced T-cells demonstrated higher naïve T-cell proportions (P<0.001), whereas exhausted T-cells and plasmablasts were not significantly altered. Among the estimated surrogate plasma proteins of GrimAge, CAR-transduced T-cells demonstrated lower beta-2 microglobulin (P<0.001), cystatin C (P=0.002), growth differentiation factor-15 (P<0.001), leptin (P=0.049), and plasminogen activator inhibitor-1 (P=0.034).

The underlying B-cell malignancy significantly modified the association between IEAA (P=0.016), SkinBloodAA (P=0.020), EEAA (P=0.018), and TLA (P=0.029). Among patients with ALL, CAR-transduced T-cells demonstrated a 22-month decrease (P=0.200) in IEAA, a 34-month decrease (P=0.119) in SkinBloodAA, a 35-month decrease (P=0.106) in EEAA, and a 0.18-unit increase (P=0.060) in TLA. Among patients with NHL, CAR-transduced T-cells exhibited a 1-month decrease (P=0.604) in IEAA, a 5-month decrease (P=0.204) in SkinBloodAA, an 8-month decrease (P=0.027) in EEAA, and a 0.05-unit increase (P=0.021) in TLA.

Conclusion: In this analysis, CAR T-cell manufacturing was significantly associated with DNA methylation-based biological aging, with CAR-transduced T-cells exhibiting younger epigenetic profiles compared to non-transduced T-cells in patients with R/R B-cell malignancies. These observations may reflect CAR T-cell manufacturing-induced epigenetic remodeling toward a less differentiated immune state, reflected by higher DNA methylation-estimated naïve T-cell proportions and reduced inflammatory signaling. The magnitude of these associations differed by B-cell malignancy, with larger reductions in biological aging observed in patients with ALL than NHL. These disease-specific differences suggest that the underlying malignancy, or potentially prior treatment exposures, may influence the epigenetic remodeling that occurs during CAR T-cell manufacturing. These findings support DNA methylation-based biological aging as a novel framework for evaluating the molecular effects of CAR T-cell manufacturing and justify further evaluation as biomarkers of treatment response and long-term clinical outcomes.

Drew R Nannini, DO, PhD: No relevant conflicts of interest to declare.